Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia

Pediatr Blood Cancer. 2007 Apr;48(4):393-8. doi: 10.1002/pbc.20824.

Abstract

Background: Extramedullary infiltration (EMI) is an occasional clinical symptom in childhood acute myelogenous leukemia (AML), but there is considerable controversy regarding the prognostic significance of EMI in AML.

Procedure: We evaluated the frequency and prognostic significance of EMI at diagnosis of AML in children.

Results: Of 240 cases of de novo AML excluding children with Down syndrome and acute promyelocytic leukemia, 56 (23.3%) showed EMI at diagnosis. Patients with EMI had a higher initial WBC count and a higher proportion of M4/M5 morphological variants. The complete remission rate following induction chemotherapy was lower in patients with EMI. However, the overall survival and event-free survival did not differ between patients with and without EMI. A detailed analysis showed that patients with EMI with a WBC count at diagnosis of over 100 x 10(9)/L or infiltration into the central nervous system are likely to have a poor prognosis.

Conclusions: CNS leukemia and EMI together with a WBC count of >100 x 10(9)/L at diagnosis of AML are high risk factors for relapse, and alternative treatment approaches for patients with these characteristics should be explored.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone and Bones / pathology
  • Central Nervous System / pathology
  • Child
  • Child, Preschool
  • Cytarabine / administration & dosage
  • Disease-Free Survival
  • Etoposide / administration & dosage
  • Female
  • Follow-Up Studies
  • Gingiva / pathology
  • Humans
  • Hydrocortisone / administration & dosage
  • Idarubicin / administration & dosage
  • Infant
  • Infant, Newborn
  • Japan / epidemiology
  • Kaplan-Meier Estimate
  • Leukemia, Myeloid / diagnosis
  • Leukemia, Myeloid / drug therapy
  • Leukemia, Myeloid / mortality
  • Leukemia, Myeloid / pathology*
  • Leukemic Infiltration / epidemiology*
  • Male
  • Methotrexate / administration & dosage
  • Orbit / pathology
  • Prognosis
  • Remission Induction
  • Sarcoma, Myeloid / drug therapy
  • Sarcoma, Myeloid / epidemiology*
  • Sarcoma, Myeloid / mortality
  • Skin / pathology
  • Testis / pathology

Substances

  • Cytarabine
  • Etoposide
  • Hydrocortisone
  • Methotrexate
  • Idarubicin